ジャーナル: PLoS Pathog / 年: 2021 タイトル: Structure-guided antibody cocktail for prevention and treatment of COVID-19. 著者: Shih-Chieh Su / Tzu-Jing Yang / Pei-Yu Yu / Kang-Hao Liang / Wan-Yu Chen / Chun-Wei Yang / Hsiu-Ting Lin / Mei-Jung Wang / Ruei-Min Lu / Hsien-Cheng Tso / Meng-Jhe Chung / Tzung-Yang Hsieh / ...著者: Shih-Chieh Su / Tzu-Jing Yang / Pei-Yu Yu / Kang-Hao Liang / Wan-Yu Chen / Chun-Wei Yang / Hsiu-Ting Lin / Mei-Jung Wang / Ruei-Min Lu / Hsien-Cheng Tso / Meng-Jhe Chung / Tzung-Yang Hsieh / Yu-Ling Chang / Shin-Chang Lin / Fang-Yu Hsu / Feng-Yi Ke / Yi-Hsuan Wu / Yu-Chyi Hwang / I-Ju Liu / Jian-Jong Liang / Chun-Che Liao / Hui-Ying Ko / Cheng-Pu Sun / Ping-Yi Wu / Jia-Tsrong Jan / Yuan-Chih Chang / Yi-Ling Lin / Mi-Hua Tao / Shang-Te Danny Hsu / Han-Chung Wu / 要旨: Development of effective therapeutics for mitigating the COVID-19 pandemic is a pressing global need. Neutralizing antibodies are known to be effective antivirals, as they can be rapidly deployed to ...Development of effective therapeutics for mitigating the COVID-19 pandemic is a pressing global need. Neutralizing antibodies are known to be effective antivirals, as they can be rapidly deployed to prevent disease progression and can accelerate patient recovery without the need for fully developed host immunity. Here, we report the generation and characterization of a series of chimeric antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Some of these antibodies exhibit exceptionally potent neutralization activities in vitro and in vivo, and the most potent of our antibodies target three distinct non-overlapping epitopes within the RBD. Cryo-electron microscopy analyses of two highly potent antibodies in complex with the SARS-CoV-2 spike protein suggested they may be particularly useful when combined in a cocktail therapy. The efficacy of this antibody cocktail was confirmed in SARS-CoV-2-infected mouse and hamster models as prophylactic and post-infection treatments. With the emergence of more contagious variants of SARS-CoV-2, cocktail antibody therapies hold great promise to control disease and prevent drug resistance.
Spikeglycoprotein / S glycoprotein / E2 / Peplomer protein
分子量: 142236.328 Da / 分子数: 1 / 由来タイプ: 組換発現 由来: (組換発現) Severe acute respiratory syndrome coronavirus 2 (ウイルス) 遺伝子: S, 2 / 発現宿主: Homo sapiens (ヒト) / 参照: UniProt: P0DTC2
#2: 抗体
RBD-chAb-25, Heavychain
分子量: 48952.828 Da / 分子数: 1 / 由来タイプ: 組換発現 / 由来: (組換発現) Homo sapiens (ヒト) / 発現宿主: Homo sapiens (ヒト)
#3: 抗体
RBD-chAb-25, Lightchain
分子量: 23415.980 Da / 分子数: 1 / 由来タイプ: 組換発現 / 由来: (組換発現) Homo sapiens (ヒト) / 発現宿主: Homo sapiens (ヒト)
Has protein modification
Y
-
実験情報
-
実験
実験
手法: 電子顕微鏡法
EM実験
試料の集合状態: PARTICLE / 3次元再構成法: 単粒子再構成法
-
試料調製
構成要素
名称: Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-25 (Focused refinement of S-RBD and chAb-25 region) タイプ: ORGANELLE OR CELLULAR COMPONENT / Entity ID: all / 由来: RECOMBINANT
分子量
実験値: NO
由来(天然)
生物種: Homo sapiens (ヒト)
由来(組換発現)
生物種: Homo sapiens (ヒト)
緩衝液
pH: 7.6
緩衝液成分
ID
濃度
名称
Buffer-ID
1
50mM
Tris
1
2
150mM
NaCl
1
3
0.02 %
sodiumazide
1
試料
包埋: NO / シャドウイング: NO / 染色: NO / 凍結: YES
急速凍結
装置: FEI VITROBOT MARK IV / 凍結剤: ETHANE / 湿度: 100 % / 凍結前の試料温度: 277 K 詳細: blot for 2.5 seconds before plunging; blot force: 0; waiting time: 30s